Alterity Therapeutics Limited (ATHE)
NASDAQ: ATHE ยท Real-Time Price ยท USD
1.700
-0.165 (-8.85%)
At close: Nov 18, 2026, 4:00 PM EST
1.740
+0.040 (2.35%)
After-hours: Nov 18, 2026, 5:52 PM EST
Alterity Therapeutics Revenue
In the fiscal year ending June 30, 2026, Alterity Therapeutics had annual revenue of 3.61M AUD, down -52.76%. Alterity Therapeutics had revenue of 806.59K in the half year ending June 30, 2026, a decrease of -61.93%.
Revenue (ttm)
3.61M AUD
Revenue Growth
-52.76%
P/S Ratio
13.24
Revenue / Employee
328,183 AUD
Employees
11
Market Cap
33.06M USD
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Jun 30, 2026 | 3.61M | -4.03M | -52.76% |
| Jun 30, 2025 | 7.64M | 3.62M | 90.12% |
| Jun 30, 2024 | 4.02M | 102.95K | 2.63% |
| Jun 30, 2023 | 3.92M | -1.21M | -23.56% |
| Jun 30, 2022 | 5.12M | 638.30K | 14.23% |
| Jun 30, 2021 | 4.49M | 4.36M | 3,554.58% |
| Jun 30, 2020 | 122.73K | -4.83M | -97.52% |
| Jun 30, 2019 | 4.95M | 1.83M | 58.40% |
| Jun 30, 2018 | 3.13M | 103.10K | 3.41% |
| Jun 30, 2017 | 3.02M | -1.87M | -38.27% |
| Jun 30, 2016 | 4.90M | -1.60M | -24.61% |
| Jun 30, 2015 | 6.49M | -1.71M | -20.89% |
| Jun 30, 2014 | 8.21M | 3.57M | 76.94% |
| Jun 30, 2013 | 4.64M | 2.11M | 83.56% |
| Jun 30, 2012 | 2.53M | 2.36M | 1,451.38% |
| Jun 30, 2011 | 162.92K | -52.09K | -24.23% |
| Jun 30, 2010 | 215.01K | -213.19K | -49.79% |
| Jun 30, 2009 | 428.19K | -62.92K | -12.81% |
| Jun 30, 2008 | 491.11K | -16.32K | -3.22% |
| Jun 30, 2007 | 507.44K | -542.85K | -51.69% |
| Jun 30, 2006 | 1.05M | -1.60M | -60.41% |
| Jun 30, 2005 | 2.65M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. It does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Veru Inc. | 16.89M |
| EyePoint | 2.58M |
| ImageneBio | 800.00K |
| Serina Therapeutics | 125.00K |
| eXoZymes | -700.00 |
ATHE News
- 7 hours ago - Alterity Therapeutics Transcript: Bell Potter Healthcare Conference - Transcripts
- 6 days ago - Alterity Therapeutics to Present at the Virtual Bell Potter Healthcare Conference - GlobeNewsWire
- 10 days ago - Alterity Therapeutics Limited - Depositary Receipt Price Target Increased by 12.50% to $8.89 - Nasdaq
- 19 days ago - Alterity Therapeutics Releases Appendix 4C โ Q1 FY27 Quarterly Cash Flow Report & Corporate Update - GlobeNewsWire
- 20 days ago - Alterity Therapeutics Earnings release: Q1 2027 - Filings
- 5 weeks ago - Alterity Therapeutics to Present at the Canaccord Genuity Drug and Device Conference - GlobeNewsWire
- 6 weeks ago - Alterity Therapeutics Presents New Analyses of ATH434 Phase 2 Data in Multiple System Atrophy at the 2026 International Congress of Parkinson's Disease and Movement Disorders - GlobeNewsWire
- 2 months ago - Alterity Therapeutics management to meet virtually with Lake Street - TheFly